Results 41 to 50 of about 117,638 (289)

Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization. [PDF]

open access: yes, 2017
BACKGROUND: The recent West African Ebola epidemic led to accelerated efforts to test Ebola vaccine candidates. As part of the World Health Organisation-led VSV Ebola Consortium (VEBCON), we performed a phase I clinical trial investigating rVSV-ZEBOV (a ...
Addo, MM   +22 more
core   +1 more source

Ebola Virus Antibody Prevalence in Dogs and Human Risk

open access: yesEmerging Infectious Diseases, 2005
During the 2001–2002 outbreak in Gabon, we observed that several dogs were highly exposed to Ebola virus by eating infected dead animals. To examine whether these animals became infected with Ebola virus, we sampled 439 dogs and screened them by Ebola ...
Loïs Allela   +8 more
doaj   +1 more source

Anti-Niemann Pick C1 Single-Stranded Oligonucleotides with Locked Nucleic Acids Potently Reduce Ebola Virus Infection In Vitro

open access: yesMolecular Therapy: Nucleic Acids, 2019
Ebola virus is the causative agent of Ebola virus disease, a severe, often fatal illness in humans. So far, there are no US Food and Drug Administration (FDA)-approved therapeutics directed against Ebola virus.
Anne Sadewasser   +9 more
doaj   +1 more source

Ebola Virüsü

open access: yesArşiv Kaynak Tarama Dergisi, 2015
Bu hastalık ismini1976'dailk kezgörüldüğü Kongo Demokratik Cumhuriyetindeki bir köye yakın olarak konumlanmış Ebola Nehrinden alır. Bu hastalığa Filoviridae ailesine mensup bir virüsten sebep olmaktadır. Ebola salgını başladığı günden bu yana temelde Batı Afrika'da yerleşim gösteren dört ülkeyi; Gine, Liberya, Sierra Leone ve Nijerya'yı ...
LAKSHMAN, Anusha   +2 more
openaire   +3 more sources

Knowledge and risk perceptions of the Ebola virus in the United States

open access: yesPreventive Medicine Reports, 2015
Objectives: The Ebola epidemic has received extensive media coverage since the first diagnosed cases of the virus in the US. We investigated risk perceptions of Ebola among individuals living in the US and measured their knowledge of the virus.
Jonathan J. Rolison, Yaniv Hanoch
doaj   +1 more source

A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa. [PDF]

open access: yes, 2017
The 2014-2015 Ebola epidemic affected several African countries, claiming more than 11,000 lives and leaving thousands with ongoing sequelae. Safe and effective vaccines could prevent or limit future outbreaks.
Agnandji, ST   +17 more
core   +2 more sources

Ebola viral selenoproteins: a metallomics analysis

open access: yesAsian Pacific Journal of Tropical Biomedicine, 2015
Ebola virus infection is the present public health problem. The trend of worldwide epidemic becomes the serious consideration for this infection. The Ebola virus infection has main clinical manifestation as acute febrile illness with hemorrhagic episode.
Somsri Wiwanitkit, Viroj Wiwanitkit
doaj   +1 more source

External Quality Assessment of Molecular Detection of Ebola Virus in China. [PDF]

open access: yesPLoS ONE, 2015
In 2014, Ebola hemorrhagic fever broke out in West Africa. As contact between China and West Africa is frequent, the possibility that Ebola virus would enter China was high.
Guojing Wang   +11 more
doaj   +1 more source

A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures

open access: yesViruses, 2020
Filoviruses, such as Ebola virus and Marburg virus, are of significant human health concern. From 2013 to 2016, Ebola virus caused 11,323 fatalities in Western Africa.
Ryan P. Bennett   +10 more
doaj   +1 more source

Wave-like spread of Ebola Zaire [PDF]

open access: yes, 2005
In the past decade the Zaire strain of Ebola virus (ZEBOV) has emerged repeatedly into human populations in central Africa and caused massive die-offs of gorillas and chimpanzees.
Leslie A Real   +3 more
core   +5 more sources

Home - About - Disclaimer - Privacy